Method Of Altering The Differentiation State Of The Cell Patents (Class 435/377)
  • Cardiac stem cells and methods for isolation of same
    Patent number: 8772030
    Abstract: Method for the isolation, expansion and preservation of cardiac stem cells from human or animal tissue biopsy samples to be employed in cell transplantation and functional repair of the myocardium or other organs. Cells may also be used in gene therapy for treating cardiomyopathies, for treating ischemic heart diseases and for setting in vitro models to study drugs.
    Type: Grant
    Filed: September 26, 2011
    Date of Patent: July 8, 2014
    Assignee: Universita Degli Studi di Roma “La Sapienza”
    Inventors: Alessandro Giacomello, Elisa Messina, Massimo Battaglia, Giacomo Frati
  • Methods for inhibiting expression of connective tissue growth factor
    Patent number: 8772260
    Abstract: This invention provides compounds which comprise modified oligonucleotides capable of inhibitory expression of connective tissue factor and composition containing same as well as methods of treating hyperprolific disorders and fibrotic diseases, and of reducing scarring resulting from wound healing using such compounds.
    Type: Grant
    Filed: August 13, 2012
    Date of Patent: July 8, 2014
    Assignees: Isis Pharmaceuticals, Inc, Excaliard Pharmaceuticals, Inc
    Inventors: Nicholas M. Dean, J. Gordon Foulkes, Niall O'Donnell, C. Frank Bennett, Susan M. Frier
  • Composition for reprogramming somatic cells to generate induced pluripotent stem cells, comprising Oct4 in combination with Bmi1 or its upstream regulator, and method for generating induced pluripotent stem cells using the same
    Patent number: 8772031
    Abstract: Disclosed is a composition for reprogramming somatic cells to generate embryonic stem cell-like cells, comprising: a) a Bmi1 (B cell-specific Moloney murine leukemia virus integration site 1) protein or a nucleic acid molecule coding for Bmi1; and b) an Oct4 protein or a nucleic acid molecule coding for Oct4. Also, a method is provided for reprogramming somatic cells to generate embryonic stem cell-like cells using the composition. In addition to reducing the number of the genetic factors conventionally needed, the composition and method allow the generation of pluripotent embryonic stem cell-like cells which have high potential in the cell therapy of various diseases.
    Type: Grant
    Filed: May 9, 2013
    Date of Patent: July 8, 2014
    Assignee: Korea University Research and Business Foundation
    Inventors: Seungkwon You, Jai-Hee Moon, Jun Sung Kim, Byung Sun Yoon, Jung Han Lee, Eun Kyoung Jun, June Seok Heo
  • CD34+CD7+CD5+CD1a-human progenitor T-cells produced in vitro and methods of using
    Patent number: 8772028
    Abstract: Human progenitor T cells that are able to successfully engraft a murine thymus and differentiate into mature human T and NK cells are described The human progenitor T cells have the phenotype CD34+CD7+CD1a?CD5? or CD34+CD7+CD1a?CD5+ and are derived from human hematopoietic stem cells, embryonic stem cells and induced pluripotent stem cells b\ coculture with cells expressing a Notch receptor ligand (OP9-DL1 or OP9-DL4) Such cells are useful in a variety of applications including immune reconstitution, the treatment of immunodeficiencies and as carriers for genes used in gene therapy.
    Type: Grant
    Filed: November 6, 2009
    Date of Patent: July 8, 2014
    Assignee: Sunnybrook Health Sciences Centre
    Inventors: Juan Carlos Zuniga-Pflucker, Geneve Awong, Ross La Motte-Mohs
  • Culturing of Human Embryonic Stem Cells At The Air-Liquid Interface For Differentiation Into Pancreatic Endocrine Cells
    Publication number: 20140186305
    Abstract: The present invention provides methods, cell cultures and differentiation media to promote differentiation of pluripotent stem cells to pancreatic endocrine cells expressing PDX1, NKX6.1, and HB9 by culturing in a culture vessel at the air-liquid interface. The invention also provides for in vivo maturation of cells cultured at the air-liquid interface.
    Type: Application
    Filed: December 18, 2013
    Publication date: July 3, 2014
    Applicant: Janssen Biotech, Inc.
    Inventor: Alireza Rezina
  • COMPOSITIONS TARGETING PKC-THETA AND USES AND METHODS OF TREATING PKC-THETA PATHOLOGIES, ADVERSE IMMUNE RESPONSES AND DISEASES
    Publication number: 20140186372
    Abstract: The invention relates to compositions, methods and uses of inhibitors of binding between PKC? and CD28, and modulating an undesirable or aberrant immune response, disorder or disease, an inflammatory response, disorder or disease, inflammation or an autoimmune response, disorder or disease. Compositions include inhibitors of binding between PKC? and CD28, which include, among others, PKC?, CD28 and Lck sequences, subsequences, variants and modified forms, and polymorphisms.
    Type: Application
    Filed: June 15, 2012
    Publication date: July 3, 2014
    Applicant: LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY
    Inventors: Amnon Altman, Kok-Fai Kong
  • GENERATION OF NEURONAL CELLS FROM PLURIPOTENT STEM CELLS
    Publication number: 20140186955
    Abstract: The invention relates to in vitro methods for differentiating mammalian pluripotent stem cells into cells displaying a neuronal phenotype, more particularly into cortical-type neurons including inter alia pyramidal neurons and cortical inhibitory interneurons. The invention further encompasses so-obtained neuronal cells and cell population, compositions comprising such, and further uses of said neuronal cells and cell population.
    Type: Application
    Filed: November 5, 2013
    Publication date: July 3, 2014
    Applicant: Universite Libre de Bruxelles
    Inventors: Pierre Vanderhaeghen, Nicolas Gaspard, Gilles Naeije, Jelle Van Den Ameele, Fabienne Devreker, Yvon Englert
  • NOTCH INDUCED NATURAL KILLER CELL GENERATION AND THERAPEUTIC USES
    Publication number: 20140186319
    Abstract: A method of preparing differentiated NK cells by ex vivo expansion includes the steps of; (1) isolating a plurality of CD34+ hematopoietic cells; (2) culturing the cells in a medium, wherein the medium includes an effective amount of a notch ligand and one or more cytokines selected from the group consisting of IL-7, IL-15, SCF, Flt-3, IL-3 and IL-6; and (3) maintaining the cells in culture for a duration of time sufficient to produce NK cells.
    Type: Application
    Filed: July 26, 2013
    Publication date: July 3, 2014
    Applicant: Case Western Reserve University
    Inventor: Rose C. Beck
  • Optimized Methods for Differentiation of Cells Into Cells with Hepatocyte and Hepatocyte Progenitor Phenotypes, Cells Produced by the Methods, and Methods for Using the Cells
    Publication number: 20140186954
    Abstract: The invention is directed to methods for culturing cells so that the cells are induced to differentiate into cells that express hepatocyte phenotypes and hepatocyte progenitor phenotypes. More particularly, the invention relates to methods for culturing cells so that the cells are induced to differentiate into cells that express a definitive endodermal phenotype, a liver-committed endodermal phenotype, a hepatoblast phenotype, and hepatocyte phenotype. The invention is also directed to cells produced by the methods of the invention. The cells are useful, among other things, for treatment of liver deficiency, liver metabolism studies, and liver toxicity studies.
    Type: Application
    Filed: September 19, 2013
    Publication date: July 3, 2014
    Applicant: Katholieke Universiteit Leuven
    Inventors: Karen Pauwelyn, Catherine M. Verfaillie
  • Differentiation of Human Embryonic Stem Cells Into Pancreatic Endocrine Cells Using HB9 Regulators
    Publication number: 20140186953
    Abstract: The present invention provides methods to promote differentiation of pluripotent stem cells to pancreatic endoderm cells expressing PDX1, NKX6.1, and HB9. In particular, the methods encompass culturing Stage 4 to Stage 6 cells with a thyroid hormone (e.g. T3), an ALK5 inhibitor, or both.
    Type: Application
    Filed: December 18, 2013
    Publication date: July 3, 2014
    Applicant: Janssen Biotech, Inc.
    Inventor: Alireza Rezania
  • SCAFFOLD-FREE TISSUE CONSTRUCTS
    Publication number: 20140186952
    Abstract: A tissue construct comprising includes a self-assembled, scaffold-free, high-density cell aggregate. The cell aggregate includes a plurality of cells and a plurality of biocompatible and degradable nanoparticles and/or microparticles that are incorporated within the cell aggregate. The nanoparticles and/or microparticles act as a bulking agent and/or provide bioactive agents or signals within the cell aggregate to increase the cell aggregate size and/or thickness and improve the mechanical properties of the cell aggregate and/or regulate cell function within the aggregate allowing the cell aggregate to be readily manipulated and formed into tissue constructs with defined architectures and potential tissue specific functionality.
    Type: Application
    Filed: April 15, 2013
    Publication date: July 3, 2014
    Applicant: Case Western Reserve University
    Inventor: Eben Alsberg
  • Reprogramming immortalized B-cells to induced pluripotent stem cells
    Patent number: 8765470
    Abstract: Methods and composition for providing induced pluripotent stem (iPS) cells are provided. For example, in certain aspects methods including reprogramming B lymphocytes transformed by episomal vectors such as Epstein-Barr virus-based vectors are described. Furthermore, the invention provides induced pluripotent stem cells essentially free of exogenous elements and having B cell immunoglobin variable region rearrangement.
    Type: Grant
    Filed: August 3, 2011
    Date of Patent: July 1, 2014
    Assignee: Cellular Dynamics International, Inc.
    Inventors: James Thomson, Deepika Rajesh, Sarah Jane Dickerson, Amanda Mack, Michael Miller
  • Methods and Compositions for In Vitro and In Vivo Chondrogenesis
    Publication number: 20140178994
    Abstract: Aspects of the present invention include methods and compositions related to the production, identification and use of embryonic progenitor cell lines that are capable of undergoing chondrogenesis. A number of exemplary chondrogenic cell lines derived from primordial stem cells are disclosed. The chondrogenic cell lines described herein are robust, can expand for >40 passages, and have site-specific purity, thus providing for compositions and methods of producing diverse cartilage types with unique molecular compositions for use in research and therapy.
    Type: Application
    Filed: February 4, 2014
    Publication date: June 26, 2014
    Applicant: BIOTIME, INC.
    Inventors: Michael West, Hal Sternberg, Karen Chapman
  • TRANSIENTLY IMMORTALIZED CELLS FOR USE IN GENE THERAPY
    Publication number: 20140178965
    Abstract: The invention provides methods and compositions for expanding cells that are not abundant or are difficult to obtain in pure form in culture, are in short supply (e.g., human cells), or have brief lifetimes in culture, using fusion polypeptide. The fusion polypeptide has a first region having the transport function of herpesviral VP22 protein or human immunodeficiency virus (HIV) TAT protein, and a second region with a polypeptide having cell immortalization activity, a polypeptide having telomerase-specific activity, or a polypeptide having telomerase gene activation activity. The resulting cells of the invention are suitable for use in cell therapy.
    Type: Application
    Filed: January 31, 2014
    Publication date: June 26, 2014
    Applicant: Heart Biosystems GMBH
    Inventors: E. Edward Baetge, Shou Wong, Philippe Dupraz, Bernard Thorens
  • Stem cell banking system
    Patent number: 8759090
    Abstract: Disclosed herein are methods for producing a stem cell bank and providing stem cell samples for purchase or use. Also, provided herein are embodiments relating to a stem cell bank and stem cell banking system.
    Type: Grant
    Filed: October 30, 2006
    Date of Patent: June 24, 2014
    Assignee: University of Central Florida Research Foundation, Inc.
    Inventors: Kiminobu Sugaya, Angel Alvarez
  • Method for cloning pluripotent stem cells
    Patent number: 8759098
    Abstract: Embodied herein are methods of reprogramming somatic cells or tissue stem cells to a more multipotent state or even a pluripotent state, the methods do not involve gene transfer of master transcription factor genes/proteins. The methods are also useful for rapid and efficient cloning of induced pluripotent stem cells after gene transfer of master transcription factor genes/proteins.
    Type: Grant
    Filed: December 3, 2010
    Date of Patent: June 24, 2014
    Assignee: Boston Biomedical Research Institute, Inc.
    Inventor: James L. Sherley
  • MULTIPOTENT STEM CELLS AND USES THEREOF
    Publication number: 20140170749
    Abstract: The invention provides a quiescent stem cell having the capacity to differentiate into ectoderm, mesoderm and endoderm, and which does not express cell surface markers including MHC class I, MHC class II, CD44, CD45, CD13, CD34, CD49c, CD73, CD105, CD90, CD66A, CD66E, CXCR4, CD133 or an SSEA. The invention further provides a proliferative stem cell, which expresses genes including Oct-4, Nanog, Sox2, GDF3, P16INK4, BMI, Notch, HDAC4, TERT, Rex-1, TWIST, KLF-4 and Stella but does not express cell surface markers including MHC class I, MHC class II, CD44, CD45, CD13, CF34, CF49c, CD73, CD105, CD90, CD66A, CD66E, CXCR4, CD133 or an SSEA. The cells of the invention can be isolated from adult mammals, have embryonic cell characteristics, and can form embryoid bodies. Methods for obtaining the stem cells, as well as methods of treating diseases and differentiated stem cells, are also provided.
    Type: Application
    Filed: October 2, 2013
    Publication date: June 19, 2014
    Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Keith D. Crawford, Christopher Southgate
  • METHOD FOR PREPARING INDUCED PLURIPOTENT STEM CELLS USING MICROVESICLES DERIVED FROM EMBRYONIC STEM CELLS
    Publication number: 20140170746
    Abstract: Provided is a method of dedifferentiating somatic cells using embryonic stem cell-derived microvesicles. Particularly, a method of preparing induced pluripotent stem cells by treating a composition including embryonic stem cell-derived microvesicles to the somatic cells. According to the method of preparing induced pluripotent stem cells, the dedifferentiation of the somatic cells may be efficiently performed without side effects using the embryonic stem cell-derived microvesicles, and moreover, the method is expected to be very useful in developing a cell therapy product having immunocompatibilities by individuals.
    Type: Application
    Filed: April 19, 2012
    Publication date: June 19, 2014
    Applicant: POSTECH ACADEMY-INDUSTRY FOUNDATION
    Inventors: Jae-Sung Park, Yong Song Gho, Yoon Keun Kim, Jun Ho Kim, Su Chul Jang, Namwoo Yi, Dayeong Jeong, Eun-Jeong Choi
  • GENERATION OF iPS CELLS AND ASSOCIATED METHODS
    Publication number: 20140170752
    Abstract: Systems, constructs, and methods for reprogramming cells are provided. In one aspect, for example, a transformation construct for generating iPS cells can include an expression vector having a plurality of reprogramming factors, each reprogramming factor being under control of a separate promoter.
    Type: Application
    Filed: August 23, 2013
    Publication date: June 19, 2014
    Applicant: University of Utah Research Foundation
    Inventors: Stefan M. Pulst, Sharan Paul, Warunee Dansithong
  • METHOD FOR PREPARING CORNEAL ENDOTHELIAL CELL
    Publication number: 20140170751
    Abstract: The present invention relates to a method for preparing corneal endothelial progenitor cells by adherent culturing a cell population isolated from corneal endothelial cell tissue at a low density by using a serum-free medium. The present invention also relates to a method for preparing corneal endothelial cells by differentiation-inducing the corneal endothelial progenitor cells obtained by the aforementioned method. According to the present invention, corneal endothelial progenitor cells can be selectively grown from a corneal tissue-derived cell population, and corneal endothelial cells obtained by inducing the corneal endothelial progenitor cells can be applied to treatment of corneal endothelial diseases. As a result, problems of corneal transplantation such as shortage of donors and occurrence of rejection can be solved.
    Type: Application
    Filed: July 13, 2012
    Publication date: June 19, 2014
    Applicant: OSAKA UNIVERSITY
    Inventors: Ryuhei Hayashi, Susumu Hara, Tomofumi Kageyama, Kohji Nishida
  • METHODS OF DIFFERENTIATING STEM CELLS BY MODULATING MIR-124
    Publication number: 20140170118
    Abstract: Provided herein are methods of differentiating stem cells via modulating miR-124, and the differentiated cells thereby. Also provided herein are methods for the treatment of diseases using the differentiated cells.
    Type: Application
    Filed: November 26, 2013
    Publication date: June 19, 2014
    Applicant: Accelerated BioSciences Corp.
    Inventors: Jau-Nan LEE, Tony Tung-Yin LEE, Yuta Lee
  • Use of a cellular extract for a mitotic remodeling of chromosomes
    Patent number: 8753887
    Abstract: The present invention relates to the use of a female germinal cell (egg) extract of pluricellular organisms in M-phase of the cell cycle for a mitotic remodeling of chromosomes of donor cells of pluricellular organisms, wherein the mitotic remodeling confers to the nucleus of the donor cells the ability to adapt themselves to the early embryonic development, in particular to the replication phases, in order to carry out the embryonic development or to obtain stem cells.
    Type: Grant
    Filed: September 29, 2006
    Date of Patent: June 17, 2014
    Assignee: Centre National de la Recherche Scientifique
    Inventors: Marcel Mechali, Jean-Marc Lemaitre
  • Method for inducing differentiation of mesenchymal stem cells to nerve cells using sound waves
    Patent number: 8753881
    Abstract: The present invention relates to a method for differentiation of mesenchymal stem cells. More specifically, the invention relates to a method for differentiating mesenchymal stem cells to neural cells by treating the mesenchymal stem cells with low-frequency sound waves. The differentiation method of the present invention can induce differentiation even with low-cost media rather than induced neural differentiation mediums which are expensive due to addition of growth factors, and the neural cells differentiated according to the present invention may be useful for treatment of neurological diseases.
    Type: Grant
    Filed: June 8, 2011
    Date of Patent: June 17, 2014
    Assignee: Dongguk University Industry-Academic Cooperation Foundation
    Inventors: Jung-Keug Park, Moon Young Yoon, Hyun Jin Cho, Young-Kwon Seo, Song Hee Jeon, Hee Hoon Yoon
  • Method of differentiation of morula or inner cell mass cells and method of making lineage-defective embryonic stem cells
    Patent number: 8753884
    Abstract: An improved method of producing differentiated progenitor cells comprising obtaining inner cell mass cells from a blastocyst and inducing differentiation of the inner cell mass cells to produce differentiated progenitor cells. The differentiated progenitor cells may be transfected such that there is an addition, deletion or alteration of a desired gene. The differentiated progenitor cells are useful in cell therapy and as a I source of cells for the production of tissues and organs for transplantation. Also provided is a method of producing a lineage-defective human embryonic stem cell.
    Type: Grant
    Filed: May 16, 2008
    Date of Patent: June 17, 2014
    Assignee: Advanced Cell Technology
    Inventors: Jose Cibelli, Michael D. West, Robert Lanza
  • GENERATION OF VASCULAR PROGENITOR CELLS
    Publication number: 20140162366
    Abstract: Provided herein are, inter alia, methods of generating vascular progenitor cells from primary cells without reprogramming the primary cell into a pluripotent stem cell. The vascular progenitors provided herein may be used to form endothelial cells or smooth muscle cells. Further provided are isolated mutlitpotent cells useful to form vascular progenitor cells.
    Type: Application
    Filed: September 3, 2013
    Publication date: June 12, 2014
    Applicant: SALK INSTITUTE FOR BIOLOGICAL STUDIES
    Inventors: Juan Carlos Izpisua Belmonte, Ignacio Sanchez-Martinez, Leo Kurian, Emmanuel Nivet
  • Differentiation of Human Embryonic Stem Cells into Pancreatic Endoderm
    Publication number: 20140162359
    Abstract: The present invention provides methods to promote the differentiation of pluripotent stem cells. In particular, the present invention provides methods to produce a population of pancreatic endoderm cells, wherein the initial seeding density of undifferentiated epluripotent cells is defined.
    Type: Application
    Filed: May 7, 2013
    Publication date: June 12, 2014
    Applicant: Janssen Biotech, Inc.
    Inventor: Janssen Biotech, Inc.
  • Method for efficient production of induced pluripotent stem cells utilizing cells derived from oral mucosa
    Patent number: 8748179
    Abstract: A main object of the present invention is to provide a technique to produce iPS cells with less burden on the patient and with high establishment efficiency. iPS cells can be efficiently produced with significantly improved establishment efficiency by selecting cells derived from oral mucosa and introducing, into the cells, reprogramming factors capable of inducing the cells into pluripotent stem cells.
    Type: Grant
    Filed: June 23, 2010
    Date of Patent: June 10, 2014
    Assignee: Osaka University
    Inventors: Hiroshi Egusa, Hirofumi Yatani, Hiroki Kayashima
  • Method for producing pluripotent stem cells
    Patent number: 8748178
    Abstract: Methods are provided for producing a human embryo capable of developing to the blastocyst stage. The method includes transferring a human somatic cell genome into a mature human oocyte by nuclear transfer and activating the oocyte, without removing the oocyte genome. Pluripotent human embryonic stem cells, and methods of obtaining these, are also provided.
    Type: Grant
    Filed: November 22, 2011
    Date of Patent: June 10, 2014
    Assignee: The New York Stem Cell Foundation
    Inventors: Dietrich M. Egli, Scott A. Noggle, Kevin C. Eggan
  • Adult cerebellum-derived neural stem cells and compositions and methods for producing oligodendrocytes
    Patent number: 8748385
    Abstract: This disclosure describes a novel population of cerebellum-derived neural stem cells that can be isolated from the adult brain, expanded, and differentiated into neurons, astrocytes and oligodendrocytes. This disclosure also describes compositions and methods for producing oligodendrocytes. Oligodendrocytes can be produced in vitro (e.g., in culture) or in vivo (e.g., for therapy or in a non-human transgenic animal) using the compositions and methods described herein.
    Type: Grant
    Filed: June 8, 2010
    Date of Patent: June 10, 2014
    Assignee: Regents of the University of Michigan
    Inventors: Kathy Sue O'Shea, Maria Morell
  • Generation of choroid plexus epithelial cells from human embryonic stem cells
    Patent number: 8748176
    Abstract: Choroid plexus epithelial cells are generated in a culture medium using embryonic stem cells and adding an effective amount of bone morphogenetic protein and/or other members of the transforming growth factor beta (TGF-beta) superfamily. Generation of such choroid plexus epithelial cells are confirmed using a combination of genetic markers, antibodies, histology inspection, functional assays, and integration into the endogenous choroid plexus in mice.
    Type: Grant
    Filed: February 9, 2012
    Date of Patent: June 10, 2014
    Assignee: The Regents of the University of California
    Inventors: Edwin S. Monuki, Momoko Watanabe
  • Compositions for proliferation of cells and related methods
    Patent number: 8748177
    Abstract: We have discovered that p63 inhibition results in increased cellular proliferation. We have also performed a screen for agents capable of increasing cellular proliferation, (e.g., of stem cells such as skin-derived precursors (SKPs)). The invention therefore invention provides compositions, methods, and kits for increasing proliferation of cells, using compounds that decrease p63 expression or activity or using the compounds described herein. The invention also features methods of using these compounds for increasing hair growth, improving skin health, or promoting skin repair in a subject.
    Type: Grant
    Filed: March 30, 2011
    Date of Patent: June 10, 2014
    Assignee: The Hospital for Sick Children
    Inventors: Freda Miller, David Kaplan, Kristen Smith, Maryline Paris, Sibel Naska
  • ENDOCRINE PRECURSOR CELLS, PANCREATIV HORMONE-EXPRESSING CELLS AND METHOS OF PRODUCTION
    Publication number: 20140154801
    Abstract: Disclosed herein are cell cultures and enriched cell populations of endocrine precursor cells, immature pancreatic hormone-expressing cells and mature pancreatic hormone-expressing cells. Also disclosed herein are methods of producing such cell cultures and cell populations.
    Type: Application
    Filed: November 5, 2013
    Publication date: June 5, 2014
    Applicant: ViaCyte, Inc.
    Inventors: Kevin A. D'Amour, Anne Bang, Emmanuel E. Baetge
  • ENHANCERS OF INDUCED PLURIPOTENT STEM CELL REPROGRAMMING
    Publication number: 20140154805
    Abstract: Described herein, inter alia, are methods and compositions useful for induced pluripotent stem cell reprogramming.
    Type: Application
    Filed: October 15, 2013
    Publication date: June 5, 2014
    Applicant: City of Hope
    Inventors: Yanhong Shi, Man Lun Yip, Wendong Li
  • Compositions and Methods Useful for Culturing Differentiable Cells
    Publication number: 20140154802
    Abstract: The present invention relates to cell culture methods and compositions that are essentially serum-free and comprise a basal salt nutrient solution and an ErbB3 ligand.
    Type: Application
    Filed: February 10, 2014
    Publication date: June 5, 2014
    Applicant: Viacyte, Inc.
    Inventors: Allan J. Robins, Thomas C. Schulz
  • MPHOSPH1 PEPTIDES AND VACCINES INCLUDING THE SAME
    Publication number: 20140154281
    Abstract: As discussed in greater detail herein, isolated epitope peptides derived from MPHOSPH1 bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines. The inventive peptides encompass both the above-mentioned MPHOSPH1-derived amino acid sequences and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted or added, provided such modified versions retain the requisite CTL inducibility of the original sequences. Further provided are polynucleotides encoding any of the aforementioned peptides as well as pharmaceutical agents or compositions that include any of the aforementioned peptides or polynucleotides.
    Type: Application
    Filed: August 9, 2012
    Publication date: June 5, 2014
    Applicant: Onco Therapy Science, Inc.
    Inventors: Takuya Tsunoda, Ryuji Osawa, Sachiko Yoshimura, Tomohisa Watanabe, Yusuke Nakamura
  • Differentiation of pluripotent stem cells to definitive endoderm lineage
    Patent number: 8741643
    Abstract: The present invention provides methods to promote the differentiation of pluripotent stem cells. In particular, the present invention provides an improved method for the formation of pancreatic endoderm, pancreatic hormone expressing cells and pancreatic hormone secreting cells. The present invention also provides methods to promote the differentiation of pluripotent stem cells without the use of a feeder cell layer.
    Type: Grant
    Filed: April 18, 2007
    Date of Patent: June 3, 2014
    Assignee: LifeScan, Inc.
    Inventors: Alireza Rezania, Jean Xu
  • Methods for producing autologous immune cells resistant to myeloid-derived suppressor cells effects
    Patent number: 8741642
    Abstract: Methods for the ex vivo generation of cells of the innate (NKT cells and NK cells) and adaptive (T cells) immune systems for use in adoptive cell transfer (ACT) are provided. The NKT cells render T cells resistant to immune suppression (e.g. they are resistant to the effects of myeloid-derived suppressor cells (MDSCs)). The method involves culturing disease-primed immune cells (obtained from a cancer patient or from a patient with an infectious disease) with i) bryostatin and ionomycin (B/I) to activate and differentiate the cells; followed by sequentially culturing the cells with a) a combination of IL-7 and IL-15 and then b) IL-2, to further differentiate the cells and to render them immune resistant. The resistant immune cells are used to treat and prevent cancer and infectious diseases.
    Type: Grant
    Filed: October 21, 2011
    Date of Patent: June 3, 2014
    Assignee: Virginia Commonwealth University
    Inventors: Masoud H. Manjili, Harry D. Bear, Maciej Kmieciak
  • Method for producing mast cells from pluripotent stem cells
    Patent number: 8741644
    Abstract: The present invention relates to a method for producing human mast cells from human pluripotent stem cells. More particularly, the present invention provides a method for producing human mast cells from human pluripotent stem cells, comprising the steps of: (a) culturing human pluripotent stem cells under a condition suitable for promoting differentiation of the human pluripotent stem cells into hematopoietic progenitor cells expressing CD34; and (b) culturing the cells obtained in step (a) in the presence of hematopoietic factors comprising thrombopoietin (TPO) and Flt3 ligand.
    Type: Grant
    Filed: September 8, 2010
    Date of Patent: June 3, 2014
    Assignee: Kyoto University
    Inventors: Tatsutoshi Nakahata, Kohichiro Tsuji, Feng Ma
  • Reprogramming T cells and hematopoietic cells
    Patent number: 8741648
    Abstract: Methods and compositions relating to the production of induced pluripotent stem cells (iPS cells) are disclosed. For example, induced pluripotent stem cells may be generated from CD34+ hematopoietic cells, such as human CD34+ blood progenitor cells, or T cells. Various iPS cell lines are also provided. In certain embodiments, the invention provides novel induced pluripotent stem cells with a genome comprising genetic rearrangement of T cell receptors.
    Type: Grant
    Filed: June 4, 2010
    Date of Patent: June 3, 2014
    Assignee: Cellular Dynamics International, Inc.
    Inventors: Deepika Rajesh, Amanda Mack
  • COMPOSITION AND METHOD TO IMPROVE THE THERAPEUTIC EFFECT OF STEM CELLS
    Publication number: 20140147420
    Abstract: The invention relates to a composition and method used for injuries treatment with a surprisingly therapeutic effect. This composition comprises a population of cells derived from human umbilical cord blood which expresses one of the following markers: CD34, CD45, and CD31; a population of CD34+ derived endothelial cells; and a biomimetic gel, preferably fibrin. The method for obtaining the composition comprises the derivation of a population of endothelial cells from CD34+ cells and then a co-culture of a CD34+ cells with CD34+-derived endothelial cells within a biomimetic gel.
    Type: Application
    Filed: November 28, 2011
    Publication date: May 29, 2014
    Applicant: Crioestaminal, Saude e Tecnologia, SA.
    Inventors: Lino Da Silva Ferreira, Dora Cristina Dos Santos Pedroso
  • COMPOSITIONS AND METHODS FOR FORMATION OF BONE TISSUE
    Publication number: 20140147419
    Abstract: Provided is a step-wise method of forming an engineered construct. Various embodiments include inducing differentiation of progenitor cells, such as embryonic stem cells; expanding the differentiated progenitor cells; combining the expanded progenitor cells and a biocompatible scaffold comprising a matrix material; and incubating the progenitor cells and the biocompatible scaffold so as to form a bone tissue module.
    Type: Application
    Filed: October 28, 2011
    Publication date: May 29, 2014
    Applicant: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventors: Gordana V. Novakovic, Darja Marolt
  • Compositions and methods for treating or ameliorating obesity or for reducing diabetic hypercholesterolemia
    Publication number: 20140148399
    Abstract: Obesity is one of the major health concerns in the Twenty-First Century and is one of the leading causes of preventable death. It is a strong risk factor for Type 2 Diabetes. Disclosed herein are compositions and methods using Nitraria retusa extracts for enhancing energy metabolism, inhibiting fat accumulation, inhibiting preadipocyte differentiation, reducing diabetic hypercholesterolemia, and for treating or ameliorating obesity.
    Type: Application
    Filed: November 26, 2012
    Publication date: May 29, 2014
    Applicants: CENTER OF BIOTECHNOLOGY OF BORJ CEDRIA, UNIVERSITY OF TSUKUBA
    Inventors: Hiroko Isoda, Junkyu Han, Zar Kalai Feten, Chedly Abdelly, Riadh Ksouri
  • METHOD OF DERIVING STEM CELLS, STEM CELLS, AND USE OF STEM CELLS FOR WOUND HEALING
    Publication number: 20140147422
    Abstract: A method of deriving isolated stem cells including: implanting a matrix in a wound site of a living organism; allowing cells to infiltrate the matrix; removing the matrix containing the infiltrated cells from the wound site; and removing the infiltrated cells from the matrix to provide isolated stem cells. Stem cells produced by this process, stem cells with certain characteristics, and methods for treating wounds using these stem cells are provided.
    Type: Application
    Filed: February 3, 2014
    Publication date: May 29, 2014
    Applicant: Embro Corporation
    Inventors: Vance D. Fiegel, David R. Knighton
  • GENERATING CK19-POSITIVE CELLS WITH HAIR-LIKE STRUCTURES FROM WHARTONS JELLY
    Publication number: 20140148915
    Abstract: A method of differentiating cells into CK19-positive cells capable of producing hair follicle-like and hair structure-like can include: providing a tissue scaffold; seeding cells into the scaffold, the cells being capable of differentiation; incubating the scaffold having the cells in a cell growth media; and incubating the scaffold having the cells in an osteogenic differentiation medium sufficient for CK19-positive cells to be generated in the scaffold. The tissue scaffold can be a decellularized Whartons' jelly matrix. The cell growth media excludes osteogenic differentiation components: dexamethasone, ?-glycerophosphate, 1?,25-hydroxyvitamin D3, and ascorbic acid 2-phosphate. The osteogenic differentiation medium includes the osteogenic differentiation components. The cells can be mesenchymal cells, such as WJMSCs.
    Type: Application
    Filed: April 30, 2013
    Publication date: May 29, 2014
    Applicants: The Children's Mercy Hospital, The University of Kansas
    Inventors: The University of Kansas, The Children's Mercy Hospital
  • COMPOSITIONS TO EFFECT NEURONAL GROWTH
    Publication number: 20140147424
    Abstract: Compositions containing neurogenic agents for inhibition of neuron death and inducing proliferation of neural cells are disclosed.
    Type: Application
    Filed: January 31, 2014
    Publication date: May 29, 2014
    Applicant: NEURALSTEM, INC.
    Inventors: Judith KELLEHER-ANDERSSON, Karl K. JOHE
  • Modulation of stem cells using zinc finger proteins
    Patent number: 8735153
    Abstract: Methods and compositions for modifying stem cells using one or more ZFPs are disclosed. Such methods and compositions are useful for facilitating processes such as, for example, dedifferentiating cells, differentiating stems cells into the desired phenotype, propagating stem cells and/or facilitating cloning.
    Type: Grant
    Filed: September 24, 2002
    Date of Patent: May 27, 2014
    Assignee: Sangamo BioSciences, Inc.
    Inventors: Michael Moore, Timothy Farries, Trevor Collingwood, Fyodor Urnov, Elizabeth J. Wolffe
  • Antisense modulation of apolipoprotein B expression
    Patent number: 8735364
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of apolipoprotein B. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding apolipoprotein B. Methods of using these compounds for modulation of apolipoprotein B expression and for treatment of diseases associated with expression of apolipoprotein B are provided.
    Type: Grant
    Filed: January 3, 2008
    Date of Patent: May 27, 2014
    Assignee: Genzyme Corporation
    Inventors: Rosanne M. Crooke, Mark J. Graham
  • High-density spot seeding for tissue model formation
    Patent number: 8735116
    Abstract: A method for making a tissue includes seeding cells at a selected concentration on a support to form a cell spot, incubating the cells to allow the cells to partially attach, rinsing the cells to remove any unattached cells, adding culture medium to enable the cells to proliferate at a periphery of the cell spot and to differentiate toward a center of the cell spot, and further incubating the cells to form the tissue. The cells may be C2C12 cells or other subclones of the C2 cell line, H9c2(2-1) cells, L6 cells, L8 cells, QM7 cells, Sol8 cells, G-7 cells, G-8 cells, other myoblast cells, cells from other tissues, or stem cells. The selected concentration is in a range from about 1×105 cells/ml to about 1×106 cells/ml. The tissue formed may be a skeletal muscle tissue, a cardiac muscle tissue, nerve tissue, or a bone tissue.
    Type: Grant
    Filed: September 13, 2010
    Date of Patent: May 27, 2014
    Assignee: The United States of America as represented by the Administrator of the National Aeronautics and Space Administration
    Inventors: Michele L. Marquette, Marguerite A. Sognier
  • Motor neurons developed from stem cells
    Patent number: 8735149
    Abstract: Provided is a method for directing differentiation of neural progenitors with a caudal and ventral specification into motor neurons including culturing neural progenitors in a culturing medium including a basic medium supplemented by at least one inhibitor of the Notch signaling pathway whereby the neural progenitors differentiate into postmitotic motor neurons. The resulting motor neurons may be used for drug development, as carriers, e.g. for gene therapy of protein delivery as well as for transplantation for the purpose of treating a motor neuron disease.
    Type: Grant
    Filed: April 5, 2009
    Date of Patent: May 27, 2014
    Assignee: Hadasit Medical Research Services & Development Limited
    Inventors: Benjamin Reubinoff, Etti Ben Shushan, Michal Aharonowiz
  • Self-Renewing Endodermal Progenitor Lines Generated from Human Pluripotent Stem Cells and Methods of Use Thereof
    Publication number: 20140141509
    Abstract: Self-renewing endodermal progenitor lines generated from human pluripotent stem cells and methods of use thereof are disclosed.
    Type: Application
    Filed: December 23, 2013
    Publication date: May 22, 2014
    Inventors: Paul Gadue, Deborah French, Xin Cheng